Liberate Bio Announces Presentation to Update on Advancements on their RAPTOR LNP Platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Liberate Bio, Inc., a company delivering genetic medicines that transcend liver-based limitations, announced an oral presentation demonstrating the success of their RAPTOR™ screening platform and its first generation of extrahepatic lipid nanoparticles at the Oligonucleotide and Peptide Therapeutics 2024 (TIDES) being held May 14-17, 2024, in Boston, Massachusetts. “We are excited to demonstrate both the establishment of our Rapid Particle Optimizer (RAPTOR™)